ArticleBMC immunology2026
Evaluation of immunoglobulin A1/immunoglobulin A2 ratio and B cell lymphoma-6 in relation to apoptosis-associated speck-like protein in diabetic kidney disease patients.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation and alteration of the immune system play a key role in the pathogenesis of diabetes mellitus (DM). However, little is known about the underlying mechanisms involved in the inflammatory pathways of diabetic kidney disease (DKD). We aimed in this study to evaluate immunoglobulin A (IgA) subclasses/ratio and B cell lymphoma-6 (BCL-6) in relation to inflammasome adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase activation and recruiting domain) in diabetic patients with and without kidney disease. The present study was conducted on 50 diabetic patients who were classified into 25 patients without kidney disease and 25 DKD patients, together with 25 age-matched healthy individuals. Enzyme-linked immunosorbent assay (ELISA) was used to assess ASC and BCL-6 levels in culture supernatants of peripheral blood mononuclear cells as well as to determine IgA1 and IgA2 levels in individuals' serum.
resultsThe results revealed a significant increase in ASC levels together with a significant decrease in IgA1 and BCL-6 levels in DKD patients compared to other groups. A significant association was observed between the IgA1/ IgA2 ratio and improved disease markers in all patients. In addition, ASC levels were negatively correlated with both IgA2 and BCL-6 levels.
conclusionsIt can be concluded that altered IgA subtypes and its ratio (IgA1/IgA2) as well as BCL-6 may be involved in the pathogenesis of DKD, suggesting their future therapeutic potential in DKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.